{"id":765300,"date":"2023-06-22T06:03:07","date_gmt":"2023-06-22T10:03:07","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/"},"modified":"2023-06-22T06:03:07","modified_gmt":"2023-06-22T10:03:07","slug":"immuron-business-update-letter-to-shareholders","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/","title":{"rendered":"Immuron Business Update: Letter to Shareholders"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">\n        <strong><br \/>\n          <em>Highlights:<\/em><br \/>\n        <\/strong><br \/>\n        \n      <\/p>\n<ul type=\"disc\">\n<li>\n          <strong>Immuron Board approves<\/strong><br \/>\n          <strong>IMM-529 cGMP manufacturing<\/strong><br \/>\n          <strong>and to<\/strong><br \/>\n          <strong>proceed with FDA pre-IND<\/strong><br \/>\n          <strong>submission<\/strong>\n        <\/li>\n<li>\n          <strong>Recruitment and screening update for Travelan\u00ae Controlled Human Infection Model (CHIM)<\/strong><br \/>\n          <strong>Clinical Trial<\/strong>\n        <\/li>\n<\/ul>\n<p>MELBOURNE, Australia, June  22, 2023  (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the following business update.<\/p>\n<p>Dear Immuron Limited Shareholders (ASX: IMC; NASDAQ: IMRN),<\/p>\n<p>Immuron is pleased to announce that it has approved proceeding with IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission.<\/p>\n<p align=\"justify\">IMM-529 was developed for treatment of <em>Clostridioides<\/em><em>difficile<\/em> (<em>C.<\/em><em>difficile<\/em>) which is an anaerobic, spore-forming, gram-positive bacillus typically associated with gastrointestinal disease. Transmission of <em>C. difficile <\/em>occurs by ingestion of spores either through person-to-person contact, animal-to-person contact or environment-to-person contact. <em>C. difficile <\/em>infection (CDI) can cause life-threatening diarrhoea and is the leading healthcare-related gastrointestinal infection in the world.<sup>1<\/sup><\/p>\n<p align=\"justify\">\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_yoGicOHCV_35s3lQVyDAC2FgxjQty6qJNMCj1Y0ZAE_34DZ_ieiWSlEuI2YxVWaILkz7YqEHBLbe0hsaQNgAA==\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n          <u>Lumanity<\/u>,<\/a> a leading lifescience consulting company conducted an opportunity assessment of IMM-529. Infectious disease experts reacted favourably to the IMM-529 mechanism of action, and its unique ability to target three elements of the CDI infection \u2013 the spores, vegetative cells, and Toxin B. Base case yearly revenue in USA for IMM- 529 was estimated at US$92M for the target patient population (limited to second recurrence and later). Positioning IMM-529 earlier than second recurrence could lead to higher uptake. The global CDI market was estimated to increase to $1.7B by 2026, according to a report by GlobalData.<sup>2<\/sup><\/p>\n<p align=\"justify\">Pharmaron have scheduled 96 telehealth screening interviews since recruitment for the planned Travelan clinical study was initiated at the end of May 2023 (ASX announcement 30 May 2023). To date 81 potential candidates have been selected for in-person screening visits which are anticipated to commence on the 28 June 2023 at Pharmaron\u2019s Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US. The Phase II clinical trial is designed to evaluate the safety and protective efficacy of Travelan\u00ae compared to a placebo in a controlled human infection model (CHIM) in up to 60 healthy participants (males or non-pregnant, non-nursing females), aged 18-50 years.<\/p>\n<p align=\"justify\">Thank you for your support.<\/p>\n<p>Steven Lydeamore Chief Executive Officer<\/p>\n<ol>\n<li>\n          <a href=\"https:\/\/www.safetyandquality.gov.au\/publications-and-resources\/resource-library\/clostridium-difficile-infection-2018-data-snapshot\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n            <strong><br \/>\n              <u>Australian<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>Commission<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>on<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>Safety<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>and<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>Quality<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>in<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>Health<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>Care<br \/><\/u><br \/>\n            <\/strong><br \/>\n          <\/a>https:\/\/www.safetyandquality.gov.au\/publications-and-resources\/resource-library\/clostridium-difficile-infection-2018-data-snapshot<\/li>\n<li>\n          <a href=\"https:\/\/www.pharmaceutical-technology.com\/research-reports\/researchreportreport-clostridium-difficile-infections-market-to-reach-17bn-by-2026-5883581\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n            <strong><br \/>\n              <u>GlobalData<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>via<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>Pharmaceutical<\/u><br \/>\n            <\/strong><br \/>\n            <strong><br \/>\n              <u>Technology<\/u><br \/>\n            <\/strong><br \/>\n          <\/a><br \/>\n          <br \/>https:\/\/www.pharmaceutical-technology.com\/research-reports\/researchreportreport-clostridium-difficile-infections-market-to-reach-17bn-by-2026-5883581<\/li>\n<\/ol>\n<p>This release has been authorised by the directors of Immuron Limited.<\/p>\n<p>\n        <strong>Contact<\/strong><br \/>\n        <strong>Information:<\/strong><br \/>\n        <br \/>Steven Lydeamore<br \/>Chief Executive Officer<br \/>Ph: +61 (0)3 9824 5254<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=dHAyev3_OH2ZTbUKAAPDWOiFikuqKY2hVUQit2cddnzNdAqzoBulOY0XUgPraNa4v4KJOdYeFRT7DkwPUBjCFw==\" rel=\"nofollow noopener\" target=\"_blank\">info@immuron.com<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=PHiwCnjCiten-HZsV_2EQ7Zs8BkOxno2DJKZ1J7Ht225ie2oPeWpOz9Z3s1Tv0D-\" rel=\"nofollow noopener\" target=\"_blank\"><br \/><\/a><\/u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cJftKEf1stUDXF1sFhpExr1We4rLpkEj_Tuore6TjH9QuSkNSYn6cL3Bkoh1Yn_qHfUHNcVIn6PeM6u6RMfZnTfJx-5ydtgS4wYNySblwF5om_Ee-f1BWh8HUv1mcg5jgKWRq-DSn3RncRDeFrZe_g==\" rel=\"nofollow noopener\" target=\"_blank\"><u>https:\/\/www.immuron.com.au\/form\/contact-us\/<\/u><\/a><\/p>\n<p align=\"justify\">\n        <strong>About<\/strong><br \/>\n        <strong> Immuron<\/strong><br \/>\n        <br \/>Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.<\/p>\n<p align=\"justify\">For more information visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0NVGNgWaHOqp5WmMDofw7c9IKjL4LRxZjdmqPZRQS44z7vCjqm2DgbGIWoAih4gxuKpKr8JnLr0YjWX4FoJtWQmrpRDLYe93NewMAaPPrt0=\" rel=\"nofollow noopener\" target=\"_blank\"><u>http:\/\/www.immuron.com<\/u><\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MjA2OTQ0OTYtN2I1OS00NDRjLWFhMGMtNDFjYWRmM2JiMzM1LTEwMzE4NjU=\/tiny\/Immuron-Limited.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission Recruitment and screening update for Travelan\u00ae Controlled Human Infection Model (CHIM) Clinical Trial MELBOURNE, Australia, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the following business update. Dear Immuron Limited Shareholders (ASX: IMC; NASDAQ: IMRN), Immuron is pleased to announce that it has approved proceeding with IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission. IMM-529 was developed for treatment of Clostridioidesdifficile (C.difficile) which is an anaerobic, spore-forming, gram-positive bacillus typically associated with &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Immuron Business Update: Letter to Shareholders&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-765300","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Immuron Business Update: Letter to Shareholders - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Immuron Business Update: Letter to Shareholders - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission Recruitment and screening update for Travelan\u00ae Controlled Human Infection Model (CHIM) Clinical Trial MELBOURNE, Australia, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the following business update. Dear Immuron Limited Shareholders (ASX: IMC; NASDAQ: IMRN), Immuron is pleased to announce that it has approved proceeding with IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission. IMM-529 was developed for treatment of Clostridioidesdifficile (C.difficile) which is an anaerobic, spore-forming, gram-positive bacillus typically associated with &hellip; Continue reading &quot;Immuron Business Update: Letter to Shareholders&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-06-22T10:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Immuron Business Update: Letter to Shareholders\",\"datePublished\":\"2023-06-22T10:03:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/\"},\"wordCount\":461,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/\",\"name\":\"Immuron Business Update: Letter to Shareholders - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=\",\"datePublished\":\"2023-06-22T10:03:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/immuron-business-update-letter-to-shareholders\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Immuron Business Update: Letter to Shareholders\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Immuron Business Update: Letter to Shareholders - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/","og_locale":"en_US","og_type":"article","og_title":"Immuron Business Update: Letter to Shareholders - Market Newsdesk","og_description":"Highlights: Immuron Board approves IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission Recruitment and screening update for Travelan\u00ae Controlled Human Infection Model (CHIM) Clinical Trial MELBOURNE, Australia, June 22, 2023 (GLOBE NEWSWIRE) &#8212; Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company that has developed two commercially available oral immunotherapeutic products for the treatment of gut mediated diseases, is pleased to provide the following business update. Dear Immuron Limited Shareholders (ASX: IMC; NASDAQ: IMRN), Immuron is pleased to announce that it has approved proceeding with IMM-529 cGMP manufacturing and to proceed with FDA pre-IND submission. IMM-529 was developed for treatment of Clostridioidesdifficile (C.difficile) which is an anaerobic, spore-forming, gram-positive bacillus typically associated with &hellip; Continue reading \"Immuron Business Update: Letter to Shareholders\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/","og_site_name":"Market Newsdesk","article_published_time":"2023-06-22T10:03:07+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Immuron Business Update: Letter to Shareholders","datePublished":"2023-06-22T10:03:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/"},"wordCount":461,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/","name":"Immuron Business Update: Letter to Shareholders - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=","datePublished":"2023-06-22T10:03:07+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODg2MjYzNSM1NjU5Njc4IzIwMjAyOTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/immuron-business-update-letter-to-shareholders\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Immuron Business Update: Letter to Shareholders"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765300","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=765300"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/765300\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=765300"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=765300"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=765300"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}